Cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking an estimated 17.9 million lives each year. Metabolic syndrome, which is involved includes abdominal obesity, high blood pressure, hyperlipidemia, hyperglycemia and low HDL cholesterol, refers to the presence of a cluster risk ...
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking an estimated 17.9 million lives each year. Metabolic syndrome, which is involved includes abdominal obesity, high blood pressure, hyperlipidemia, hyperglycemia and low HDL cholesterol, refers to the presence of a cluster risk factors specific for CVDs and strongly increase the risk of developing CVDs. It is well accepted that metabolic syndrome management can strongly results in improvements in major cardiovascular disease events. However, the drug discovery process for metabolic disease and CVDs is still facing with several challenges that impact the development of effective and safe medications.
To promote cardiovascular therapeutic development in this domain, here we organize this special topic and provide a scientific forum for cardiovascular scientists, endocrinologist, and cardiovascular surgeons to present their newest findings in characterizing the relationship between metabolic disease and cardiovascular disease.
We welcome the submission of high-quality manuscripts to this special topic.
Keywords:
metabolic disease, cardiovascular disease, therapeutics, drug discovery
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.